{"entity":{"id":"genie","kind":"collection","name":"AACR Project GENIE","aka":[],"tldr":"AACR Project GENIE is real-world tumour sequencing data shared by leading cancer centres.","summary":"AACR Project GENIE holds clinico-genomic data on more than 200,000 sequenced tumours contributed by 19 institutions, making it a real-world tumour sequencing resource shared by leading cancer centres. The data are open through cBioPortal and Synapse, and the project is run by the American Association for Cancer Research (AACR). Its Biopharma Collaborative adds detailed outcomes for non-small cell lung, colorectal, breast, prostate, pancreatic and bladder cancers. On OnCo it is linked to the term Real-world evidence and cited by the bottlenecks Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Data silos and Secrecy and intellectual property block collaboration, and by ideas such as Emulate the trial in real-world data first to decide which trials to run.","asOf":"2026-09-04","links":[{"label":"AACR Project GENIE","url":"https://www.aacr.org/professionals/research/aacr-project-genie/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aacr"],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.aacr.org/professionals/research/aacr-project-genie/","holds":"Clinico-genomic data on >200,000 sequenced tumours from 19 institutions.","license":"Open (via cBioPortal and Synapse)","maintainer":"AACR"},"route":"/collections/genie/","neighbours":{"institution":[{"id":"aacr","kind":"institution","name":"American Association for Cancer Research (AACR)","route":"/institutions/aacr/"}],"term":[{"id":"oncotree-term","kind":"term","name":"OncoTree cancer classification","route":"/terms/oncotree-term/"},{"id":"real-world-evidence","kind":"term","name":"Real-world evidence","route":"/terms/real-world-evidence/"},{"id":"targeted-panel-sequencing","kind":"term","name":"Targeted panel sequencing","route":"/terms/targeted-panel-sequencing/"}],"bottleneck":[{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/"},{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/"},{"id":"b-ip-collaboration","kind":"bottleneck","name":"Secrecy and intellectual property block collaboration","route":"/bottlenecks/b-ip-collaboration/"},{"id":"b-tumor-heterogeneity","kind":"bottleneck","name":"Tumour heterogeneity and clonal evolution","route":"/bottlenecks/b-tumor-heterogeneity/"}],"idea":[{"id":"idea-bio2-rapid-autopsy-commons","kind":"idea","name":"A global rapid tissue donation network for metastatic disease","route":"/ideas/idea-bio2-rapid-autopsy-commons/"},{"id":"idea-bio2-organotropism-atlas","kind":"idea","name":"An organotropism atlas that predicts where a cancer will spread","route":"/ideas/idea-bio2-organotropism-atlas/"},{"id":"idea-bio2-antigen-presentation-triage","kind":"idea","name":"Check whether a tumour can still show itself to the immune system","route":"/ideas/idea-bio2-antigen-presentation-triage/"},{"id":"idea-tr2-rwe-combination-emulation","kind":"idea","name":"Emulate combination trials from real-world data to triage which ones to run","route":"/ideas/idea-tr2-rwe-combination-emulation/"},{"id":"idea-tr1-target-trial-emulation-to-prioritise-rcts","kind":"idea","name":"Emulate the trial in real-world data first to decide which trials to run","route":"/ideas/idea-tr1-target-trial-emulation-to-prioritise-rcts/"},{"id":"idea-data-structured-genomic-reports","kind":"idea","name":"Every tumour genomic report machine-readable and deposited nationally","route":"/ideas/idea-data-structured-genomic-reports/"},{"id":"idea-bio2-patient-partnered-rare-commons","kind":"idea","name":"Let patients themselves donate their records and samples for ultra-rare cancers","route":"/ideas/idea-bio2-patient-partnered-rare-commons/"},{"id":"idea-data-registry-genomics-linkage-programme","kind":"idea","name":"Link every national cancer registry to tumour genomics","route":"/ideas/idea-data-registry-genomics-linkage-programme/"},{"id":"idea-bio2-io-biomarker-data-commons","kind":"idea","name":"Pool every immunotherapy trial's biomarker data into one commons","route":"/ideas/idea-bio2-io-biomarker-data-commons/"},{"id":"idea-bio2-registry-embedded-randomisation","kind":"idea","name":"Randomise inside the registry that already follows every patient","route":"/ideas/idea-bio2-registry-embedded-randomisation/"},{"id":"idea-tr1-validate-real-world-progression-endpoints","kind":"idea","name":"Validate real-world progression endpoints so pragmatic trials can use them","route":"/ideas/idea-tr1-validate-real-world-progression-endpoints/"}],"journal":[{"id":"jco-precision-oncology","kind":"journal","name":"JCO Precision Oncology","route":"/journals/jco-precision-oncology/"}],"roadmap":[{"id":"drug-discovery-roadmap","kind":"roadmap","name":"Drug discovery roadmap: screening in mice → maps of dependency → designing in silico","route":"/roadmaps/drug-discovery-roadmap/"}]}}